Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1677
This examiner grants 14% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19102345 | METHOD FOR FIXING PRIMARY ANTIBODIES TO A BIOLOGICAL SAMPLE | Non-Final OA | PIXELGEN TECHNOLOGIES AB |
| 17479326 | METHODS AND ASSAYS FOR IMMUNE PHENOTYPING | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17386733 | BIOMARKERS FOR CONGENITAL VASCULAR MALFORMATIONS | Non-Final OA | University of South Carolina |
| 16838623 | METHOD FOR EVALUATION OF TARGET IN HISTOLOGICAL SAMPLE | Non-Final OA | Agilent Technologies, Inc. |
| 17768671 | METHOD IN BIOPROCESS PURIFICATION SYSTEM | Non-Final OA | Cytiva BioProcess R&D AB |
| 18016538 | Methods and Compositions for Diagnosing and Treating Cancer | Non-Final OA | La Jolla Institute for Immunology |
| 17269108 | MULTIPLEX DEVICE UTILIZING LINEAR ARRAY WITH SLANTED TEST LINES ON A LATERAL FLOW STRIP OR MICROFLUIDIC DEVICE | Non-Final OA | INTELLIGENT MATERIAL SOLUTIONS, INC. |
| 18114229 | DROPLET ORGANOID-BASED IMMUNO-ONCOLOGY ASSAYS AND METHODS OF USING SAME | Non-Final OA | Xilis, Inc. |
| 17295608 | METHODS AND KIT FOR ASSAYING LYTIC POTENTIAL OF IMMUNE EFFECTOR CELLS | Non-Final OA | UNIVERSITÉ PAUL SABATIER TOULOUSE III |
| 17220888 | RAPID MULTIPLEXED SEROLOGICAL TEST | Final Rejection | Genalyte, Inc. |
| 17160661 | BIOMARKER, METHODS, AND COMPOSITIONS THEREOF FOR EVALUATION OR MANAGEMENT OF KIDNEY FUNCTION OR DIAGNOSING OR AID IN DIAGNOSING KIDNEY DYSFUNCTION OR KIDNEY DISEASE | Non-Final OA | SEQUELA, INC. |
| 17049004 | COMPOSITIONS AND METHODS FOR EVALUATING POTENCY OF LISTERIA-BASED IMMUNOTHERAPEUTICS | Non-Final OA | ADVAXIS, INC. |
| 16572364 | NOVEL PREGNANCY DIAGNOSIS DEVICE INCLUDING BETA-CORE FRAGMENT HCG AS MARKER | Final Rejection | ADTECH CO., LTD. |
| 16326369 | LATERAL FLOW ASSAY FOR ASSESSING RECOMBINANT PROTEIN EXPRESSION OR REPORTER GENE EXPRESSION | Final Rejection | Qoolabs, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy